Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0H1GJ
|
||||
Former ID |
DAP001240
|
||||
Drug Name |
Sulfamerazine
|
||||
Synonyms |
Cremomerazine; Kelamerazine; Mebacid; Mesulfa; Methylpyrimal; Methylsulfadiazine; Methylsulfazin; Methylsulfazine;Metilsulfadiazin; Metilsulfazin; Percoccide; Pyralcid; Romezin; Septacil; Septosyl; Solfamerazina; Solumedin; Sulfameradine; Sulfamerazin; Sulfamerazina; Sulfamerazinum; Sulfamethyldiazine; Sulphamerazine; Sumedine; Pyrimal M; Solfamerazina [DCIT]; RP 2632; A-310; Debenal-M; Pirimal-M; Sulfamerazina [INN-Spanish]; Sulfamerazine (INN); Sulfamerazinum [INN-Latin]; Veta-Merazine; Sulfamerazine [USAN:INN:BAN]; N-(4-Methyl-2-pyrimidyl)sulfanilamide; N1-(4-Methyl-2-pyrimidinyl)sulfanilamide; N1-(4-Methylpyrimidin-2-yl)sulfanilamide; N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)-(8CI); (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [German]; 2(p-Aminobenzolsulfonamido)-4-methylpyrimidin; 2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine; 2-(Sulfanilamido)-4-methylpyrimidine; 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidine; 2-Sulfa-4-methylpyrimidine; 2-Sulfanilamido-4-methylpyrimidine; 2643-RP; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide (9CI); 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10:A00-B99] | Approved | [538336] | ||
Therapeutic Class |
Antiinfective Agents
|
||||
Structure |
Download2D MOL |
||||
Formula |
C11H12N4O2S
|
||||
Canonical SMILES |
CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N
|
||||
InChI |
1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
|
||||
InChIKey |
QPPBRPIAZZHUNT-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 127-79-7
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
87814, 603126, 3206553, 4484323, 7849493, 8149534, 8153268, 10321119, 10506257, 11112279, 11335738, 11360977, 11362757, 11365319, 11367881, 11372205, 11373884, 11376043, 11461949, 11466722, 11467842, 11485155, 11486504, 11489136, 11491178, 11492158, 11493817, 14742044, 14799063, 24870500, 24899818, 26611926, 26679865, 26748261, 26748262, 29224379, 46505036, 47291106, 47515295, 47810729, 47885384, 47959712, 48259203, 48259204, 48416571, 49698731, 50048752, 50086854, 57322711, 57650870
|
||||
SuperDrug ATC ID |
D06BA06; J01ED07
|
||||
SuperDrug CAS ID |
cas=000127797
|
||||
Target and Pathway | |||||
Target(s) | Dihydropteroate synthetase | Target Info | Inhibitor | [537591] | |
References | |||||
Ref 537591 | A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim and Dapsone residues in muscle by ultra-high-performance liquid chromatography-tandem mass spectrometry according to Commission Decision 2002/657/EC. J Chromatogr A. 2009 Jun 9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.